1. Gauci M-L, Aristei C, Becker JC, et al. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline—update 2022. Eur J Cancer. 2022;171:P203–31.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Merkel cell carcinoma version 1. 2023. https://www.nccn.org. Accessed 26 Apr 2023.
3. Incyte Corporation. ZYNYZ™ (retifanlimab-dlwr) injection, for intravenous use: US prescribing information. 2023. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.proces. Accessed 26 Apr 2023.
4. U.S. Food & Drug Administration. FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma. [media release] 22 Mar 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel.
5. Incyte Corporation. Pharmaceutical portfolio. 2023. https://www.incyte.com/what-we-do/pharmaceutical-portfolio. Accessed 26 Apr 2023.